A practical reference on pentadecapeptide: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2026-01-18 and is reviewed periodically as new material appears.
Direct human evidence is scarce. One trial in ulcerative colitis delivered the compound by enema and produced limited publicly reported results without a clear benefit. The compound is not an approved medicine in most jurisdictions. In many markets it is sold as a research chemical; in others it falls under prescription or controlled categories. Regulators have not confirmed any claimed medical use, and product labels rarely undergo premarket review.
Most published reports describe experiments in rodents rather than in people. These studies examine outcomes in tendons, ligaments, bone, stomach lining, and intestinal tissue. In rat and mouse models, a frequently reported effect is faster healing or reduced damage. Sample sizes are usually small, and a substantial share of the work originates from a small number of research groups. Independent replication is limited, so how far the findings extend to humans remains an open question.
Proposed mechanisms in the literature involve the nitric oxide system, vascular endothelial growth factor signaling, and epidermal growth factor receptor pathways. Some studies report changes in blood vessel formation or in inflammatory mediators, while others describe interactions with nervous tissue. Much of this evidence rests on molecular markers in cultured cells or animal models. Whether the same pathways operate the same way in humans has not been established. Authors therefore tend to describe mechanisms as hypothetical rather than settled.
Most early work on this peptide originated in the 1990s from a research group in Zagreb, Croatia, relying on animal models and cell cultures. Reported observations included effects on gastrointestinal lesion healing, tendon fibroblast migration, and blood vessel formation under controlled laboratory conditions. These findings come predominantly from rodent studies and in vitro assays rather than from human trials. Controlled human data remain limited, and the degree to which animal results translate to human physiology is an open question rather than a settled fact.
Within the research literature, the peptide is discussed through several provisional mechanisms, including cytoprotection, modulation of growth factor signaling, and interaction with the nitric oxide system. None of these mechanisms is fully characterized, and no single pathway is universally accepted. Review articles typically note the gap between consistent animal findings and sparse human evidence. The compound is classified as a research chemical rather than an approved pharmaceutical, which shapes how studies are designed, funded, and reported.
BPC-157 is a synthetic pentadecapeptide with the sequence GEPPPGKPADDAGLV, corresponding to a partial fragment of a larger protein detected in human gastric juice. The name derives from the parent protein designation BPC, an abbreviation of body protection compound, with 157 acting as a fraction or batch identifier used by the original investigators. Its molecular weight is approximately 1419 daltons, and the chain contains no unusual residues or disulfide bridges. In the literature it is described as a short, water-soluble fragment rather than a complete natural protein.
| Property | Value | Notes |
|---|---|---|
| Main study model | Rodents, rats and mice | Underpins most of the published data |
| Common routes in studies | Subcutaneous, intraperitoneal, oral | Varies with the experimental design |
| Common analytical method | Reversed-phase HPLC, LC-MS | Used for identity and purity checks |
| Human evidence base | Small | Few trials reported, with limited findings |
| Regulatory status | Varies by jurisdiction | Not an approved medicine in most places |
BPC-157 is a synthetic peptide composed of fifteen amino acids. Its sequence corresponds to part of a protein found in human gastric juice, which is the origin of the "body protection compound" label. In laboratory work the material is treated as a defined research chemical rather than a finished product. Published research has centered on animal models, and the peptide is not an approved medicine in most countries.
The peptide was first described in the early 1990s by a group studying gastric secretions and tissue repair. Its fifteen-residue chain is usually written as GEPPPGKPADDAGLV in single-letter code. The free peptide has the formula C62H98N16O22 and a theoretical mass near 1419.5 daltons. These identifiers are established chemical facts that can be checked against standard peptide databases. There is no ambiguity about the primary structure.
Purity is ordinarily reported as a percentage from reverse-phase high-performance liquid chromatography, where the area of the main peak is compared with the total peak area. Identity is confirmed by mass spectrometry, since the measured mass can be checked against the value calculated from the sequence. Some certificates also include amino acid analysis or sequence confirmation by tandem mass spectrometry. A single purity number does not describe the profile of related impurities, so the underlying chromatogram and spectrum usually carry more information than the headline figure.
Material of this kind is sold for laboratory research, and labels typically state that it is not intended for human or veterinary use. In many countries it is not an approved medicine, and sports antidoping rules place it among prohibited non-approved substances. Buyers commonly review a certificate of analysis, an independent test report, and the declared storage conditions. Batch-to-batch variation in purity and in counterion content is possible, and how much that variation affects experimental outcomes remains an open question.
Lyophilized peptide is normally kept at minus twenty degrees Celsius or colder, away from light and moisture. Powder held under those conditions is widely treated as stable for long periods, although published stability studies for this exact sequence are sparse and often come from suppliers rather than independent laboratories. Once dissolved, solutions are generally handled cold and used within a short window, because peptide bonds can hydrolyze over time. Repeated freeze-thaw cycles are usually avoided to limit losses, and exact shelf-life figures depend on the buffer and the concentration involved.
BPC-157 is a synthetic peptide composed of fifteen amino acid residues, with the sequence Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val. Its name derives from body protection compound, a term used for a protein fraction identified in human gastric juice. Researchers in Zagreb first reported the pentadecapeptide in the early 1990s and described it as a stable fragment of that larger protein. The compound is also catalogued as PL 14736 and, in some commercial contexts, as bepecin. Its molecular formula is C62H98N16O22 and its monoisotopic mass is approximately 1419 daltons.
Most published work on BPC-157 consists of preclinical studies, including rodent models of tissue injury, gastrointestinal lesions, and vascular or tendon damage, together with in vitro cell assays. Reviews frequently note that the mechanisms proposed in these papers remain incompletely characterised and that findings have not been confirmed in large randomised human trials. The compound is widely sold as a research chemical rather than a licensed medicine, and labels commonly carry a statement that it is not for human use. Whether any of the reported animal effects translate to humans is an open question rather than an established result.
Terminology in the literature is not fully standardised. Papers and product listings use BPC-157, BPC 157, and the longer phrase stable gastric pentadecapeptide BPC 157 interchangeably, and synonyms such as bepecin or PL 14736 appear in older or company-linked publications. Purity claims and reported masses can also differ between sources because peptide preparations may include counterions, residual solvents, or bound water. This variability complicates direct comparison of results across studies and makes the exact identity and grade of a given sample worth verifying. Discussions of the compound should therefore specify the source, salt form, and stated purity where those are known.
In its usual supplied form, the peptide is a white to off-white lyophilized powder that dissolves readily in water and in aqueous buffers. Powder keeps far longer than solution, so material is normally shipped and stored dry, then dissolved only when needed. Once in solution, the chain is subject to hydrolysis and the liquid supports microbial growth, and practical guidance generally treats the dissolved form as short-lived. Containers should stay sealed and desiccated, because the powder takes up moisture from air.
Long-term storage of the dry powder is typically described at minus twenty degrees Celsius or colder, while shorter holding periods may use ordinary refrigeration. Repeated warming and cooling cycles are discouraged because they stress the material and can promote aggregation or loss. Light exposure and residual moisture are both treated as avoidable sources of degradation, and working aliquots are often prepared to limit how many times a container is opened. Sealed vials with a desiccant are the usual container.
Quality assessment rests on two separate questions: whether the chain is the intended one, and how much of the sample is that chain. Reverse-phase high-performance liquid chromatography with ultraviolet detection is the standard purity measurement, while mass spectrometry confirms identity through the observed molecular mass. Amino acid analysis and sequence verification provide further checks. A reported purity percentage describes the proportion of the sample represented by the main peak, not the amount of peptide by mass, since counter-ions and water make up part of any lyophilized lot.
=== Myopathies with central nuclei === Myopathies with central nuclei, such as myotubular myopathy, involves an error in the gene involved in vesicle movement throughout the cell. This creates problems in vesicles reaching the plasma membrane with the cellular components necessary to fuse myoblast, a major step in the formation of the skeletal muscle. This creates structural problems throughout the skeletal muscle and in the Z line of the sarcomere, creating the weakness in the muscle.
3) Regulations 1993 (S.I. 1993/1540) Firearms (Dangerous Air Weapons) (Scotland) Amendment Rules 1993 (S.I. 1993/1541) First Community National Health Service Trust (Change of Name) Order 1993 (S.I. 1993/1543) Mental Health Foundation of Mid Staffordshire National Health Service Trust (Change of Name) Order 1993 (S.I. 1993/1544) Special Trustees for the Royal London Hospital (Transfer of Trust Property) Order 1993 (S.I. 1993/1545) Child Resistant Packaging (Safety) (Amendment) Regulations 1993 (S.I. 1993/1546) Toys (Safety)(Amendment) Regulations 1993 (S.I. 1993/1547) Addenbrooke's National Health Service Trust (Transfer of Trust Property) Order 1993 (S.I. 1993/1564) Foreign Fields (Specification) (Amendment) Order 1993 (S.I. 1993/1565) Foreign Fields (Specification) (No. 2) Order 1993 (S.I. 1993/1566) Reconstitution of the Dearne and Dove Internal Drainage Board Order 1993 (S.I. 1993/1570) European Communities (Designation)(No. 2) Order 1993 (S.I. 1993/1571) House of Commons Disqualification Order 1993 (S.I. 1993/1572) Child Abduction and Custody (Parties to Conventions) (Amendment) (No. 2) Order 1993 (S.I. 1993/1573) Extradition (Hijacking) (Amendment) Order 1993 (S.I. 1993/1574) Iraq (United Nations) (Sequestration of Assets) (Isle of Man) Order 1993 (S.I. 1993/1575) Family Law (Northern Ireland) Order 1993 (S.I. 1993/1576) Family Law (Northern Ireland Consequential Amendments) Order 1993 (S.I. 1993/1577) Fire Services (Amendment) (Northern Ireland) Order 1993 (S.I. 1993/1578) Social Security (Amendment) (Northern Ireland) Order 1993 (S.I.
=== Transfer between bacteria === Gram-negative bacteria can develop and transfer β-lactam resistance (including carbapenem resistance) in many ways. They can generate new extended-spectrum β-lactamases (ESBL) from the existing spectrum of plasmid-mediated β-lactamases through amino acid substitution. They can acquire genes encoding ESBL from environmental bacteria. They can increase the expression of chromosome-encoded β-lactamase genes (bla genes) due to regulatory gene and promoter sequence modifications. They can mobilize bla genes through integrons or horizontal transfer of genomic islands into other gram-negative species and strains. They can disseminate plasmid-mediated carbapenemases. Finally, they can lower or even inhibit the expression of porin genes. Three major classes of enzymes are involved in carbapenem resistance: class A carbapenemases, class B metallo-β-lactamases (MBL), and class D β-lactamases (OXA). The four known groups of class A carbapenemases are: SME (three types associated with S. marcescens), IMI (present in E. cloacae), GES (16 variants thus far found in P. aeruginosa predominantly but also found in K. pneumoniae and E. coli), and KPC (10 types of K. pneumoniae carbapenemase). At the UVA Medical Center, a transfer mechanism of KPC-dependent carbapenem resistance was discovered in the transmission of a plasmid carrying the transposon (Tn4401), which contains the KPC gene (blaKPC), to several bacteria including Enterobacter cloacae, Klebsiella oxytoca, E. coli, and Citrobacter freundii.
Public transportation in and around Raleigh is provided by GoRaleigh (formerly Capital Area Transit), which operates 33 fixed bus routes, including the R-Line. Although there are 33 routes, some routes are designed to cover multiple other routes at times when they are not served. Depending on the time of the day, and the day of the week, the number of routes operating is between 5 and 29. Raleigh is also served by GoTriangle (formerly Triangle Transit Authority). GoTriangle offers scheduled, fixed-route regional and commuter bus service between Raleigh and the region's other principal cities of Durham, Cary and Chapel Hill, as well as to and from the Raleigh-Durham International Airport, Research Triangle Park and several of the region's larger suburban communities. Triangle Transit also coordinates an extensive vanpool and rideshare program that serves the region's larger employers and commute destinations. North Carolina State University also maintains its own transit system, the Wolfline, that provides zero-fare bus service to the general public along multiple routes serving the university's campuses in southwest Raleigh. Government agencies throughout the Raleigh-Durham metropolitan area have struggled with determining the best means of providing fixed-rail transit service for the region. From 1995 the cornerstone of Triangle Transit's long-term plan was a 28-mile rail corridor from northeast Raleigh, through downtown Raleigh, Cary, and Research Triangle Park, to Durham using DMU technology.
Sources: en.wikipedia.org
Calcium gluconate is the calcium salt of gluconic acid and is used as a mineral supplement and medication. As a medication it is used by injection into a vein to treat low blood calcium, high blood potassium, and magnesium toxicity. Supplementation is generally only required when there is not enough calcium in the diet. Supplementation may be done to treat or prevent osteoporosis or rickets. It can also be taken by mouth but is not recommended for injection into a muscle. Side effects when injected include slow heart rate, pain at the site of injection, and low blood pressure. When taken by mouth side effects may include constipation and nausea. Blood calcium levels should be measured when used and extra care should be taken in those with a history of kidney stones. At normal doses, use is regarded as safe in pregnancy and breastfeeding. Calcium gluconate is made by mixing gluconic acid with calcium carbonate or calcium hydroxide. Calcium gluconate came into medical use in the 1920s. It is on the World Health Organization's List of Essential Medicines. Calcium gluconate is available as a generic medication. It is closely related to calcium borogluconate, which is commonly used in veterinary medicine owing to its higher solubility. It is used for intravenous administration of calcium, notably in ruminants.
Besides being a physical barrier, the sulcular epithelium is able to release antimicrobial peptides which retard the growth of bacteria.This is through the secretion of defensins (β-defensins (hBD-1 and hBD-2)) which are a unique feature of the sulcular epithelium as compared to the junctional epithelium. However if plaque build-up occurs due to the lack of proper oral hygiene practices, bacteria are able to adhere to the sulcular epithelium using their fimbriae. It is discovered that the biofilm adhered to the sulcular epithelium consists of a rich content of glycocalyces, suggesting that these virulence factors allow the survival and colonisation of the periodontal pathogens. The fimbriae then induces the inflammatory response via the release of proinflammatory cytokines, leading to bone resorption. During periodontal disease, the epithelial barrier of the sulcular epithelium becomes discontinuous or ulcerated, compromising the integrity of these junctional complexes. This results in an increase in epithelial permeability and facilitates the passage of bacterial products. This is further promoted through the non-keratinised nature of the epithelium which also acts as a semi-permeable membrane. The transport of harmful bacterial products into the gingiva allows the detection of bacteria action which allows the sulcular epithelium to retaliate through the diffusion of the gingival crevicular fluid (GCF) containing inflammatory cells (neutrophils & small lymphocytes) & inflammatory mediators (IL-8, CXCL8 chemokines) into the sulcus.
== Uses == Spermidine can be used in electroporation while transferring the DNA into the cell under the electrical impulse. May be used for purification of DNA-binding proteins. Spermidine is also used, along with calcium chloride, for precipitating DNA onto microprojectiles for bombardment with a gene gun. Spermidine has also been reported to protect the heart from aging and prolong the lifespan of mice, while in humans it was correlated with lower blood pressure. It also was found to reduce the amount of aging in yeast, flies, worms, and human immune cells by inducing autophagy. Spermidine may play a role in male and female fertility. Fertile men have higher spermidine levels than men who are infertile, and spermidine supplementation has been shown to help maintain a healthy hormone balance and reduce oxidative stress. Spermidine is commonly used for in vitro molecular biology reactions, particularly, in vitro transcription by phage RNA polymerases, in vitro transcription by human RNA polymerase II, and in vitro translation. Spermidine increases specificity and reproducibility of Taq-mediated PCR by neutralizing and stabilizing the negative charge on DNA phosphate backbone.
Sources: en.wikipedia.org
Animal experiments form the bulk of the published record. Rodent models of tendon, ligament, bone, and gut injury are the most common designs. Controlled human trials are rare, which limits confidence in any clinical claim.
They are best described as working hypotheses. Supporting data come mainly from cell cultures and animal tissue, using markers such as growth factors and inflammatory signals. Confirmatory human studies have not been reported.
Status depends on the country. In some places it is treated as a research chemical available without a prescription, while elsewhere it falls under prescription or controlled rules. It holds no general marketing approval as a therapeutic product.
The sequence corresponds to a fragment of a protein found in human gastric juice, so related sequences are natural. The isolated fifteen-amino-acid peptide supplied for research is produced synthetically. Whether the free fragment circulates naturally in humans has not been settled.